Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats

GLP-1 ad battle—Ozempic and Wegovy maker responds to Hims & Hers Super Bowl debut
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Millions Will See This Super Bowl Ad. Health Experts (and Two Senators) Aren’t Pleased.
The spot makes lofty claims about weight-loss drugs offered by the telehealth company Hims & Hers, but says little about ...
Hims & Hers faces scrutiny from senators on Super Bowl ad that ‘risks misleading' patients
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
STAT12d
Ozempic approved for chronic kidney disease patients
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Is the promise of more affordable weight loss drugs too good to be true? Compounded semaglutide, explained.
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
San Francisco company airs controversial Super Bowl ad despite multiple objections
San Francisco-headquartered telehealth company Hims & Hers is at the heart of one of the biggest controversies during the Super Bowl. Hims & Hers, which has its headquarters in the Marina District, ...